Lineage Cell Therapeutics
Develops off-the-shelf cell-replacement therapies for retinal, spinal-cord, hearing and corneal disease.
Something off on this page? Send us feedback.
Profile
Develops off-the-shelf allogeneic cell-replacement therapies from pluripotent stem cells, generating collaboration and license-related revenue while candidates remain investigational. Its shared AlloSCOPE platform supports retinal, spinal-cord, hearing and corneal programs, with OpRegen licensed to Roche/Genentech.
Develops off-the-shelf, allogeneic cell-replacement therapies from pluripotent stem cells, using its AlloSCOPE manufacturing platform to create differentiated cells for damaged tissues. Revenue comes principally from collaboration, licensing and research obligations rather than product sales, with no approved therapy or established sales infrastructure.
The portfolio spans OpRegen retinal-pigment-epithelium cells for geographic atrophy, OPC1 oligodendrocyte progenitor cells for spinal-cord injury, ReSonance for hearing loss, COR1 for corneal disease, and early manufacturing and photoreceptor programs. Roche/Genentech holds worldwide rights to OpRegen, while internal programs share development and manufacturing work.
All therapeutic candidates remain investigational. Manufacturing is centered at its Jerusalem subsidiary, so commercialization depends on clinical results, regulatory review, specialized delivery, scalable cell production, collaborators and a single manufacturing site.
Company facts
Key statistics
Year to date −32.0% · Average volume (30d) 954.1K
Analysts
No analyst consensus on record.
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026Q2 FY26 | −$0.03 | −$0.03 | −5.9% | $1.8M | $1.1M | −42.0% | −2.65% |
| May 12, 2026Q1 FY26 | −$0.02 | −$0.03 | −50.0% | $3.6M | $1.7M | −52.1% | −3.76% |
| Mar 5, 2026Q4 FY25 | −$0.04 | $0.00 | +109.2% | $2.0M | $6.6M | +236.8% | +0.54% |
| Nov 6, 2025Q3 FY25 | −$0.02 | −$0.13 | −550.0% | $2.0M | $3.7M | +87.8% | +1.73% |
Financial highlights
| 11 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.5M | $2.8M | $3.7M | $6.6M | $1.7M | $1.1M | |
| Gross profit | $1.5M | $2.7M | $3.7M | $6.5M | $1.5M | $882.0K | |
| Operating income | −$6.5M | −$19.8M | −$3.8M | −$6.5M | −$7.6M | −$8.9M | |
| Net income | −$4.1M | −$30.5M | −$29.8M | $851.0K | −$4.8M | $1.5M | |
| Diluted EPS | −$0.02 | −$0.13 | −$0.13 | $0.00 | −$0.02 | $0.01 | |
| Gross margin | 97.6% | 98.6% | 99.9% | 99.0% | 89.1% | 82.5% | |
| Operating margin | -433.1% | -715.4% | -102.9% | -99.1% | -440.2% | -834.7% |
Fiscal years (4-quarter sums)FY24 $9.5M · FY25 $14.6M
Revenue by product · Q2 FY26
Revenue by geography · FY25
Balance sheet, Jun 30, 2026Cash & short-term investments $50.8M · Total debt $2.3M · Total assets $106.2M · Shareholders' equity $60.9M
Dividends
No dividends on record.
Ownership
Shares outstanding 249.30M · Float 236.53M · 94.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Neal C. Bradsher | 57.85M | 23.10% | 13D | Nov 14, 2025 |
| Broadwood Capital Inc | 49.56M | 19.88% | 13F | May 15, 2026 |
| BlackRock, Inc. | 13.19M | 5.30% | 13G | Jul 29, 2026 |
| Chernett Jorey | 11.45M | 5.00% | 13G | Sep 26, 2025 |
| Vanguard Capital Management LLC | 8.32M | 3.34% | 13F | May 15, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Biogen
SYFOVRE is the leading commercial treatment for geographic atrophy.
- AbbVie
C5 inhibition for geographic atrophy, plus retinal gene therapy.
- Regeneron
Phase 3 C5 therapy and a large retinal-specialist franchise.
- NervGen Pharma
Neuroreparative recovery therapy for spinal-cord injury.
- Sana Biotechnology
Hypoimmune iPSC islet-cell therapy and cell-engineering overlap.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Lineage Cell Therapeutics | $1.11 | −0.45% | $276.7M | — | — | 21.2 | −61.3% |
| Biogen | $218.19 | −0.14% | $32.28B | 38.7 | 16.5 | 3.2 | +3.4% |
| AbbVie | $255.80 | +0.13% | $451.38B | 72.0 | 16.8 | 7.0 | +10.2% |
| Regeneron | $793.21 | −0.11% | $81.82B | 19.6 | 13.1 | 5.3 | +16.7% |
| NervGen Pharma | $2.27 | 0.00% | $187.4M | — | — | — | — |
| Sana Biotechnology | $3.95 | +0.51% | $1.09B | — | — | — | — |
| Median | 38.7 | 16.5 | 5.3 | +10.2% |